U.S. Removes Barriers for Early-Stage Drug Trials, Making Clinical Speed a New Battleground in Biotech Competition
HHS and the FDA are focusing reform on the narrow bottlenecks before and after first-in-human trials: clarifying regulatory expectations earlier, preserving flexibility in trial design, and using remote tools and real-world data to broaden participation. The balance of this acceleration effort will depend on whether speed can advance alongside participant protection.